Evidence map›Paper›PMID 39206291›Full record

ArticleFrontiers in neurology2024

CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome.

Durjoy Lahiri, Bruna Seixas-Lima, Carlos Roncero, Nicolaas Paul Verhoeff, Morris Freedman, Sarmad Al-Shamaa, Howard Chertkow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Durjoy LahiriBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.
Bruna Seixas-LimaBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.
Carlos RonceroBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.
Nicolaas Paul VerhoeffBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.
Morris FreedmanBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.
Sarmad Al-ShamaaBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.
Howard ChertkowBaycrest Academy for Research and Education/Rotman Research Institute, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: With the advent of anti-β-amyloid therapies, clinical distinction between Aβ + and Aβ- in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays. Methods: Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q), and imaging characteristics were collected from 52 subjects with possible/probable AD. Results: Participants with Aβ+ status had lower baseline MMSE scores (24.50 vs. 26.85, Discussion: Clinical β-Amyloid Positivity Prediction Score is a simple clinical tool for use in primary care and memory clinic settings to predict β-amyloid positivity in individuals with clinical Alzheimer Syndrome can potentially facilitate referral for Anti Aβ therapies.

Indexed as

Alzheimeramyloid-betaCAPSclinicalearly diagnosispredictivity

Identifiers

PMID39206291
PMCPMC11349651

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.